IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?

Fernanda Costa Brandão Berti; Karen Brajão de Oliveira; Fernanda Costa Brandão Berti; Karen Brajão de Oliveira

doi:10.3934/Allergy.2018.2.88

AIMS Allergy and Immunology

2018, Volume 2, Issue 2: 88-97. doi: 10.3934/Allergy.2018.2.88

Previous Article Next Article

Mini review Topical Sections

IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?

Fernanda Costa Brandão Berti ^1,2,
Karen Brajão de Oliveira ^{1,2
,
,}

1.
Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Londrina State University, Londrina, Parana, Brazil
2.
Departamento de Ciências Patológicas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Campus Universitário, CEP 86051-970, Londrina, Paraná, Brazil

Received: 27 April 2018 Accepted: 18 June 2018 Published: 26 June 2018

It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from in vitro and in vivo murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.
- IL-10,
- cancer,
- immunosuppression,
- immunostimulation,
- protumor activity,
- antitumor activity
Citation: Fernanda Costa Brandão Berti, Karen Brajão de Oliveira. IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?[J]. AIMS Allergy and Immunology, 2018, 2(2): 88-97. doi: 10.3934/Allergy.2018.2.88

Related Papers:

Abstract

It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from in vitro and in vivo murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.

References

[1]	Gopal M (2015) Role of cytokines in tumor immunity and immune tolerance to cancer, In: Rezaei N, Cancer Immunology: A Translational Medicine Context, 1 Ed., Heidelberg-New York-Dordrecht-London: Springer, 93–120.
[2]	Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883–899. doi: 10.1016/j.cell.2010.01.025
[3]	Mannino MH, Zhu Z, Xiao H, et al. (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367: 103–107. doi: 10.1016/j.canlet.2015.07.009
[4]	Mumm JB, Oft M (2013) Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity. Bioessays 35: 623–631. doi: 10.1002/bies.201300004
[5]	Saraiva M, Christensen JR, Veldhoen M, et al. (2009) Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31: 209–219. doi: 10.1016/j.immuni.2009.05.012
[6]	Trifunović J, Miller L, Debeljak Ž, et al. (2015) Pathologic patterns of interleukin 10 expression -a review. Biochem Med 25: 36–48.
[7]	Sato T, Terai M, Tamura Y, et al. (2011) Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy. Immunol Res 51: 170–182. doi: 10.1007/s12026-011-8262-6
[8]	Yoon BS, Kim YT, Kim JW, et al. (2007) Expression of human leukocyte antigen‑G and its correlation with interleukin‑10 expression in cervical carcinoma. Int J Gynecol Obstet 98: 48–53. doi: 10.1016/j.ijgo.2007.03.041
[9]	Cosman D, Müllberg J, Sutherland CL, et al. (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123–133. doi: 10.1016/S1074-7613(01)00095-4
[10]	Moretta L, Bottino C, Pende D, et al. (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18: 151–158. doi: 10.1016/j.smim.2006.03.002
[11]	Groh V, Wu J, Yee C, et al. (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734–738. doi: 10.1038/nature01112
[12]	Gasser S, Orsulic S, Brown EJ, et al. (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186–1190. doi: 10.1038/nature03884
[13]	Smyth MJ, Swann J, Cretney E, et al. (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202: 583–588. doi: 10.1084/jem.20050994
[14]	Koebel CM, Vermi W, Swann JB, et al. (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903–907. doi: 10.1038/nature06309
[15]	Urosevic M, Dummer R (2003) HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 13: 337–342. doi: 10.1016/S1044-579X(03)00024-5
[16]	Szekeres-Bartho J (2002) Immunological relationship between the mother and the fetus. Int Rev Immunol 6: 471–495.
[17]	Noguchi K, Isogai M, Kuwada E, et al. (2004) Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res 24: 3387–3392.
[18]	Curigliano G, Criscitiello C, Gelao L, et al. (2013) Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 19: 5564–5571. doi: 10.1158/1078-0432.CCR-12-3697
[19]	Lin A, Yan WH (2015) HLA-G expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med 21: 782–791.
[20]	Riteau B, Rouas-Freiss N, Menier C, et al. (2001) HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 8: 5018–5026.
[21]	Seo N, Hayakawa S, Tokura Y (2002) Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 12: 291–300. doi: 10.1016/S1044-579X(02)00015-9
[22]	Roncarolo MG, Gregori S, Battaglia M, et al. (2006) Interleukin‑10‑secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28–50. doi: 10.1111/j.0105-2896.2006.00420.x
[23]	Achyut BR, Arbab AS (2016) Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Oncotargets Ther 1: 1047–1055.
[24]	Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukocyte Biol 78: 1043–1051. doi: 10.1189/jlb.0705358
[25]	Lauw FN, Pajkrt D, Hack CE, et al. (2000) Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 5: 2783–2789.
[26]	Kobayashi T, Matsuoka K, Sheikh SZ, et al. (2011) NFIL3 is a regulator of IL-12 p40 in macrophages and mucosal immunity. J Immunol 8: 4649–4655.
[27]	Mumm JB, Emmerich J, Zhang X, et al. (2011) IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 6: 781–796.
[28]	Emmerich J, Mumm JB, Chan IH, et al. (2012) IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 72: 3570–3581. doi: 10.1158/0008-5472.CAN-12-0721
[29]	Parato KG, Kumar A, Badley AD, et al. (2002) Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. Aids 16: 1251–1256. doi: 10.1097/00002030-200206140-00007
[30]	Mocellin S, Panelli MC, Wang E, et al. (2003) The dual role of IL-10. Trends Immunol 1: 36–43.
[31]	Mantovani A, Sozzani S, Locati M, et al. (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 11: 549–555.
[32]	Janjic BM, Lu G, Pimenov A, et al. (2002) Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 4: 1823–1830.
[33]	Kelly JM, Darcy PK, Markby JL, et al. (2002) Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 1: 83–90.
[34]	Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 4: 201–208.

Reader Comments

Your name:*

Email:*
© 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)